Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Ilies Benotmane^{1,2} MD, Gabriela Gautier -Vargas¹ MD, Noelle Cognard¹ MD, Jerome
Olagne¹ MD, Francoise Heibel¹ MD, Laura Braun-Parvez¹ MD, Jonas Martzloff¹ MD, Peggy
Perrin¹ MD, Bruno Moulin^{1,2} MD, PhD, Samira Fafi-Kremer^{2,3} MD, PhD, Sophie Caillard^{1,2}
MD, PhD

¹*Department of Nephrology and Transplantation, University Hospital, Strasbourg, France*

²*Fédération de Médecine Translationnelle (FMTS), Strasbourg, France*

³*Department of virology, University Hospital, Strasbourg, France*

Corresponding author: Ilies Benotmane, Department of Nephrology and Transplantation,
Strasbourg University Hospital, 1 Place de l'Hopital, 67091 Strasbourg, Cedex, France.

E-mail address: Ilies.benotmane@chru-strasbourg.fr

Keyword: kidney transplant recipient, COVID-19 vaccine

Abstract

Data concerning the anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in kidney transplant recipients (KTRs) are currently lacking. Here, we sought to examine this issue by analyzing the serological response observed in 241 KTRs after a first vaccine injection. Our results indicate that KTRs have a weak anti-SARS-CoV-2 antibody response, ultimately resulting in a low seroconversion rate (26/241, 10.8%). This phenomenon likely stems from a high immunosuppression burden in this clinical population.

International recommendations on COVID-19 vaccine distribution have given priority to immunocompromised patients – including kidney transplant recipients (KTRs).^{1,2}

Unfortunately, this guidance has been released without inclusion of this clinical population in vaccine clinical trials. In an effort to shed light on the efficacy and safety of an mRNA COVID-19 vaccine in KTRs, this preliminary study was undertaken to investigate the anti-SARS-CoV-2 antibody response after the first injection. The protocol was reviewed and approved by the local Institutional Review Board (approval number: DC-2013–1990).

We examined 242 KTR who received the first injection of the Moderna mRNA-1273 vaccine (100 µg) at the Strasbourg University Hospital (France) between January 21 and 28, 2021. All had a negative history for COVID-19 and tested negative for anti-SARS-CoV-2 antibodies on the day of the first injection. The anti-SARS-CoV-2 antibody response was assessed at 28 days post-injection using the ARCHITECT IgG II Quant test (Abbott, Abbott Park, IL, USA), with titers >50 AU/mL being considered as positive.

One patient developed mild symptomatic COVID-19 seven days after injection and only 26 (10.8%) KTRs had a positive serology at 28 days post-injection. The median IgG titer was 224 AU/mL (interquartile range: 76–496 AU/mL). Patients who seroconverted had longer time from transplantation, received less immunosuppression, and had a better kidney function (Table 1).

In summary, the burden of immunosuppression may induce a weak anti-SARS-CoV-2 antibody response in KTRs after the first injection of an mRNA COVID-19 vaccine. This finding is strikingly different compared with immunocompetent subjects – who invariably seroconverted after the first injection.^{3,4} We highlight the need not to delay the second vaccine injection in immunocompromised patients. Close surveillance is also recommended to discuss the opportunity of a third dose in less responsive patients.

References

1. COVID-19 Vaccination Program Operational Guidance | CDC.
<https://www.cdc.gov/vaccines/covid-19/covid19-vaccination-guidance.html>. Accessed March 1st, 2021.
2. ECDC. <https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf>. Accessed March 1st, 2021.
3. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *N Engl J Med*. 2020;383(20):1920-1931.
4. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. *The Lancet*. 2021;0(0).

Table 1 Characteristics of kidney transplant recipients according to serological response after the first dose of the Moderna mRNA-1273 vaccine

	Entire cohort (n=241*)	SARS-CoV-2 seronegative patients (n=215)	SARS-CoV 2 seropositive patients (n=26)	p	Missing data
Age (years)	57.7 (49.3-67.6)	57.7 (49.6-67.7)	58.4 (43.3--66.9)	0.51	0
Male sex	156 (64.7%)	142 (66.1%)	14 (53.9%)	0.28	0
BMI (kg/m²)	25.7 (22.6-29.5)	25.7 (22.8-29.4)	26.4 (21.9-29.9)	0.73	2
Time from kidney transplantation (years)	6.4 (2.9-13)	5.8 (2.8-11.9)	15.4 (8.6-25.9)	<0.001	2
First transplantation	202 (83.8%)	176 (81.8%)	26 (100%)	0.01	0
Deceased donor	192 (79.6%)	172 (80%)	20 (76.9%)	0.8	0
ABO Group				0.02	2
O	94 (39.3%)	82 (38.5%)	12 (46.2%)		
A	101 (42.3%)	93 (43.7%)	8 (30.8%)		
B	30 (12.6%)	29 (13.6%)	1 (3.9%)		
AB	14 (5.9%)	9 (4.2%)	5 (19.2%)		
Induction treatment				0.001	7
Anti-thymocyte globulin	138 (59.5%)	127 (60.8%)	11 (47.8%)		9
Anti-CD25	88 (37.9%)	80 (38.3%)	8 (34.8%)		
No induction	6 (2.6%)	2 (1%)	4 (17.4%)		
CNI				0.06	0
Tacrolimus	133 (55.2%)	124 (57.7%)	9 (34.6%)		
Ciclosporin	82 (34%)	69 (32.1%)	14(50%)		
No CNI	26 (10.8%)	22 (10.2%)	4 (15.4%)		
MMF/MPA	191 (79.3%)	177 (82.3%)	14 (53.9%)	0.002	0
Imurel	7 (2.9%)	4 (1.86%)	3 (11.5%)	0.03	0
mTOR inhibitors	35 (14.5%)	32 (14.9%)	3 (11.6%)	1	0
Steroids	142 (58.9%)	133 (61.9%)	9 (34.6%)	0.01	0
Belatacept	9 (3.8%)	9 (4.2%)	0	0.26	0
eGFR (mL/min/1.73m²)	51.6 (38.1-68)	51 (37.9-66.5)	64.9 (39.9-72.2)	0.08	0
Serum creatinine (μmol/L)	118 (99-158)	120 (101-159)	104 (85-134)	0.05	0

*The patient who developed COVID-19 after the first injection was excluded from the analysis.

Continuous variables are presented as medians (interquartile ranges), whereas categorical variables are presented as counts (percentages).

Abbreviations: BMI, body mass index; CNI, calcineurin inhibitors; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; MPA, mycophenolic acid